MedImmune and Infinity Pharmaceuticals Announce Cancer Drug Development and...
– Alliance to Focus on Novel, Targeted Small Molecule Cancer Therapeutics in Two Key Programs - GAITHERSBURG, Md. and CAMBRIDGE, Mass., Aug. 28 /PRNewswire-FirstCall/ — MedImmune, Inc. (Nasdaq: MEDI)...
View ArticleInfinity and MedImmune Announce Promising Biological Activity of Anti-Hsp90...
– Data Presented at AACR-NCI-EORTC Conference Supports Expansion of Clinical Development for IPI-504 – PRAGUE, Czech Republic, Nov. 7 /PRNewswire-FirstCall/ — Infinity Pharmaceuticals, Inc. (Nasdaq:...
View ArticleMedImmune’s Advancing Cancer Pipeline to Be Highlighted at the American...
ORLANDO, Fla., Dec. 9 /PRNewswire-FirstCall/ — MedImmune, Inc. (Nasdaq: MEDI) announced today that results from three programs within the company’s expanding oncology pipeline will be presented at the...
View ArticleInfinity and MedImmune Initiate Phase I/II Clinical Trial of IPI-504 for...
Expansion of IPI-504 Development Into Second Solid Tumor Indication Highlights Potential Breadth of Novel Hsp90 Inhibitor CAMBRIDGE, Mass. and GAITHERSBURG, Md., Feb. 14, 2007 (PRIME NEWSWIRE) —...
View ArticleInfinity and MedImmune to Present Preclinical Data From Study of Oral...
CAMBRIDGE, Mass. and GAITHERSBURG, Md., Apr 10, 2007 (PrimeNewswire via COMTEX News Network) — Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) and MedImmune, Inc. (Nasdaq:MEDI) today announced that data...
View ArticleInfinity and MedImmune Announce Updated Data On Ipi-504 to be Presented At ASCO
CAMBRIDGE, Mass. and GAITHERSBURG, Md., May 31, 2007 (PrimeNewswire via COMTEX News Network) — Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) and MedImmune, Inc. (Nasdaq:MEDI) today announced that...
View ArticleInfinity and MedImmune Receive Orphan Drug Designation for IPI-504 for...
CAMBRIDGE, Mass. and GAITHERSBURG, Md., Sept. 17, 2007 (PRIME NEWSWIRE) — Infinity Pharmaceuticals, Inc. (NasdaqGM:INFI – News) and MedImmune today announced that the U.S. Food and Drug...
View ArticleInfinity and MedImmune Announce Issuance of U.S. Patent for Proprietary Heat...
– Companies Also Granted European Orphan Drug Designation for IPI-504 for the Potential Treatment of Gastrointestinal Stromal Tumors – CAMBRIDGE, Mass. and GAITHERSBURG, Md. — October 23, 2007 —...
View Article
